GNI Group, Ltd. (TSE: 2160, "the Company") today completed the procedures to acquire all shares of Ayumi Pharmaceutical Holdings Co., Ltd. from shareholders led by Blackstone. As a result, Ayumi Pharmaceutical Holdings Co., Ltd. and its subsidiary, Ayumi Pharmaceutical Corporation, will become wholly owned subsidiaries of the Company. Since our founding in 2001 and listing in 2007, aiming for global expansion as a Japanese company, we have developed businesses in China, the United States, and Australia. Meanwhile, we have long positioned our pharmaceutical foundation in Japan as a "missing piece" and have continuously explored all possibilities, including partnerships and M&A. With this acquisition, we have obtained the final piece in the optimal form and now position this as our "Second Founding Period (True Global Founding Period)". As a global biopharmaceutical company capable of demonstrating strong synergy across Japan, the US, China, and Australia, we will move forward to the next stage of sustainable growth. Ayumi Pharmaceutical is a pharmaceutical company with a solid earnings base, strong in pain management, including "Calonal," which has been favored in medical settings as an antipyretic and analgesic for over 40 years. Its domestic market share for acetaminophen formulations exceeds 80% (83%), and its sales revenue for the fiscal year ending March 2026 is approximately 38.5 billion yen. The acquisition price (valuation of approximately 44.8 billion yen) was settled through cash and the issuance of new GNI Group shares. With this transaction, we also welcome Blackstone, Toho Holdings, and Hisamitsu Pharmaceutical as new shareholders. Following the completion of this acquisition, the company name of Ayumi Pharmaceutical and all current product brand names, including the flagship product Calonal® (acetaminophen), will be maintained. We will fully respect Ayumi Pharmaceutical's high presence as a specialty pharmaceutical company in the orthopedic and rheumato